Abstract
References
- 1. Altiok N, Bessereau JL, Changeux, JP. ErbB3 and ErbB2/neu mediate the effct of heregulin on acetylcholine receptor gene expresssion in muscle: diffrential expression at the endplate. EMBO Journal 1995;14(17):4258-66. 2. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75. 3. Wilson TR, Fridlyand J, Yan Y et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487:505-9. 4. Gijs M, Penner G, Blackler GB et al. Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer. Pharmaceuticals 2016; 9:29. 5. Zhu G, Zhang H, Jacobson O et al. Combinatorial Screening of DNA Aptamers for Molecular Imaging of HER2 in Cancer”, Bioconjug Chem 2017; 28(4):1068-75. 6. Mahlknecht G, Maron R, Mancini M et al. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci USA 2013; 110(20):8170-75. 7. Gong H, Kovar J, Little G et al. In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specifi affidy molecule labeled with a near-infrared florophore. Neoplasia 2010; 12:139-49. 8. Dent S, Oyan B, Honig A et al. HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials. Cancer Treatment Reviews 2013; 39:622-31. 9. Kümler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treatment Reviews 2014; 40(2);259- 70.
HER2 Reseptörüne Karşı Geliştirilen DNA Aptamerlerin Meme Kanserinde Tanı ve Tedavi Amaçlı Kullanılması
Abstract
Bu çalışmada, HER2-pozitif (HER2+) meme kanser hücrelerinde biyobelirteç olarak HER2
reseptörünü hedef alan DNA aptamerler kullanarak ileride HER2+ kanser hücrelerine selektif
diyagnostik testler geliştirmeyi ve sitotoksik ilaçları hedefe yönelik bir şekilde kanser hücrelerine
taşımayı amaçladık. Gastrik tümör hücrelerinde HER2 yüzey antijenlerini tanıdığı bildirilen
monomerik ve trimerik HER2 DNA aptamer sekanslarının HER2+ meme kanser hücrelerine
selektif olarak bağlanıp bağlanmadığını test ettik. Bu nedenle HER2 DNA aptamer sekansların
5 ucuna IRD 800 bağlanarak işaretlendi. IRD 800 işaretli monomerik ve trimerik HER2 DNA
aptamer sekanslarının meme kanser hücrelerinde HER2 reseptörlerini hedeflme yetenekleri
karşılaştırıldı. Buna göre, HER2 reseptör protein düzeylerine paralel olarak, IRD 800 işaretli
DNA aptamer sekansları yüksek oranda HER2 ekspresyonu görülen MDA MB 453 ve SKBR3
meme kanser hücrelerine yoğun şekilde bağlanırken, hiç HER2 ekspresyonu görülmeyen MDA
MB 231 hücrelerine çok az spesifik olmayan bağlanma görüldü.
Keywords
References
- 1. Altiok N, Bessereau JL, Changeux, JP. ErbB3 and ErbB2/neu mediate the effct of heregulin on acetylcholine receptor gene expresssion in muscle: diffrential expression at the endplate. EMBO Journal 1995;14(17):4258-66. 2. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75. 3. Wilson TR, Fridlyand J, Yan Y et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487:505-9. 4. Gijs M, Penner G, Blackler GB et al. Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer. Pharmaceuticals 2016; 9:29. 5. Zhu G, Zhang H, Jacobson O et al. Combinatorial Screening of DNA Aptamers for Molecular Imaging of HER2 in Cancer”, Bioconjug Chem 2017; 28(4):1068-75. 6. Mahlknecht G, Maron R, Mancini M et al. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci USA 2013; 110(20):8170-75. 7. Gong H, Kovar J, Little G et al. In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specifi affidy molecule labeled with a near-infrared florophore. Neoplasia 2010; 12:139-49. 8. Dent S, Oyan B, Honig A et al. HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials. Cancer Treatment Reviews 2013; 39:622-31. 9. Kümler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treatment Reviews 2014; 40(2);259- 70.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Research article |
| Authors | |
| Publication Date | March 30, 2020 |
| Acceptance Date | March 3, 2020 |
| Published in Issue | Year 2020 Volume: 3 Issue: 1 |
All site content, except where otherwise noted, is licensed under a Creative Common Attribution Licence. (CC-BY-NC 4.0)
